Pharmacyclics, Inc. (PCYC)

Displacement (92.15) Submitted: 9/28/2009 5:31:22 PM : Start Price: $1.99 PCYC Score: +17.64

This swine flu mover has turned the corner and lost its momentum. It's just not worth $2.

darkflame (96.80) Submitted: 7/3/2007 10:20:51 AM : Start Price: $5.40 PCYC Score: -53.27

... the insider buying in PHARMACYCLICS, INC is not real insider, but a benefial owner, which happens to be a company called Robert W Duggan, check http://www.dugganassociates.com

Now...the problem is, most of these money management companies don't beat the markets, specially the ones focusing in small stocks. I checked what they said in the page and they "predict future prices"... well, and I say, they can do that because nobody else can.
Robbert W Duggan sells bad funds and invest in stocks in a way that will yield random results.

I checked their fee structure...a very tipical money scam, 20% of the profits!!! Likely they will take high risks to have high profits, if all the money is lost they won't have to pay 20% of what you lost.... so, one more case of unbalanced probabilities relating to rewards.

I regret having picked this company, I think it's time to read more about the company, then lick my wounds and close it.

biotiempo (53.31) Submitted: 4/4/2007 10:18:26 AM : Start Price: $4.91 PCYC Score: -46.45

After the Dendreon panel recommendation, Pharmacyclics made a filing with the FDA that among other things seeks a review of Xcytrin by an outside panel of experts. This coupled with lung cancer advocacy group involvement increases the chances of a favorable outcome regarding FDA approval.

GatorFan1990 (< 20) Submitted: 1/19/2007 4:04:00 PM : Start Price: $5.10 PCYC Score: -48.71

NDA filed for Xcytrin and with Fast Track status should have a response from the FDA by June 2007. Insider buying activity is very bullish indicating they think they'll get approval. Company owns 100% of all North America revenue with expectations of capturing 50% of the 150K cases per year for Brain Mets in the US. Comparing to other companies rev/patient might bring $14K. Do that math and this could get very interesting as the year goes by.

erictao (< 20) Submitted: 12/22/2006 3:02:58 PM : Start Price: $4.98 PCYC Score: -49.01

In the right domain and has substaintail for growth

OldCountryBuffet (49.06) Submitted: 12/6/2006 11:04:03 PM : Start Price: $5.40 PCYC Score: -51.12

Revolutionary treatments for cancer should take this pharmaceutical a long way. Insider buying shows clinical testing is going well.

5STARsmallCAPS (< 20) Submitted: 11/24/2006 1:02:25 PM : Start Price: $6.15 PCYC Score: -56.47

5-star $130 million market cap on 11/24/06
Pharmaceutical R&D - small molecule inhibitors.
5STARsmallCAPS picks five star stocks with the smallest market caps.

BukaHuka (77.69) Submitted: 11/1/2006 1:42:38 PM : Start Price: $5.23 PCYC Score: -52.82

Insiders like it, maybe some successful tests coming up.